Since individuals with type 2 diabetes have CD34+ cells expressing high levels of PAI-1, their CD34+ cells theoretically will benefit from having levels of PAI-1 reduced toward a normal, non-diabetic range prior to the use of these cells as an autologous cell therapy. This evidence concerns the gene SERPINE1 and type 2 diabetes mellitus.